Weiss Multi-Strategy Advisers’s Viking Therapeutics VKTX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-218,799	Closed	-$4.07M	–	462
2023 Q4	$4.07M	Buy	218,799 +4,625	+2%	+$60.5K	0.1%	267
2023 Q3	$2.37M	Sell	214,174 -71,274	-25%	-$1.02M	0.06%	357
2023 Q2	$4.63M	Buy	285,448 +160,549	+129%	+$3.36M	0.09%	304
2023 Q1	$2.08M	Buy	+124,899	New	+$1.29M	0.05%	417
2019 Q2	–	Sell	-10,000	Closed	-$99K	–	642
2019 Q1	$99K	Sell	10,000 -10,000	-50%	-$83.7K	﹤0.01%	490
2018 Q4	$153K	Sell	20,000 -98,000	-83%	-$1.17M	0.01%	420
2018 Q3	$2.06M	Buy	118,000 +33,000	+39%	+$393K	0.05%	326
2018 Q2	$807K	Buy	+85,000	New	+$565K	0.02%	463

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Weiss Multi-Strategy Advisers's VKTX Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Viking Therapeutics (VKTX) in Q1 2024, closing a stake of 218,799 shares — an estimated $4.07M sold.

Weiss Multi-Strategy Advisers first reported a position in VKTX in Q2 2018 and held it in 8 quarters. The position peaked at $4.63M in Q2 2023. 375 funds tracked by Wall St. Rank hold VKTX as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Viking Therapeutics position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 218,799 Viking Therapeutics shares in Q1 2024, an estimated $4.07M.
Weiss Multi-Strategy Advisers first reported a position in Viking Therapeutics in Q2 2018 and held it in 8 quarters.
Weiss Multi-Strategy Advisers's Viking Therapeutics position peaked at $4.63M in Q2 2023.
375 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.